Diagonal is advancing its lead program to treat the underlying cause of hereditary hemorrhagic telangiectasia (HHT)
WATERTOWN, Mass., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Diagonal Therapeutics, a biotechnology company pioneering a new approach to discovering and developing agonist antibodies, today announced they will participate in multiple presentations at Cure HHT's upcoming 15th HHT International Scientific Conference, taking place in Mandelieu-la-Napoule, France, October 15-19th, 2024. HHT is a severely debilitating bleeding disorder caused by mutations in ALK1 or Endoglin genes. These mutations lead to severe nosebleeds and gastrointestinal bleeds that lead to transfusion-dependent anemia. People with HHT are also at risk for life-threatening arteriovenous malformation (AVM) ruptures in critical organs such as the liver, lungs, and brain. The disease affects roughly 150,000 people in the United States and European Union.